{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5029","pValueComment":"Stratified by region, prior biologic use, RF status, and treatment.","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0495","pValueComment":"Stratified by region, prior biologic use, RF status, and treatment.","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.9"},{"groupId":"OG001","value":"27.7"},{"groupId":"OG002","value":"10.8"}]}],"title":"None"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.7"},{"groupId":"OG001","value":"55.5"},{"groupId":"OG002","value":"62.4"}]}],"title":"Moderate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4"},{"groupId":"OG001","value":"16.8"},{"groupId":"OG002","value":"26.9"}]}],"title":"Good"}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"93"}],"units":"Participants"}],"description":"EULAR responses were categorized according to DAS28-ESR score. DAS28-ESR ≤ 3.2 at Week 48 and a change from BL to Week 48 \\< -1.2 = good response, DAS28-ESR ≤ 3.2 or greater than (\\>) 3.2 and ≤ 5.1 at Week 48 and a change from BL to Week 48 \\< -0.6 and ≥ -1.2 = moderate response, DAS28-ESR \\> 3.2 and ≤ 5.1 at Week 48 and a change from BL to Week 48 \\< -1.2 = moderate response, DAS28-ESR \\> 5.1 at Week 48 and a change from BL to Week 48 \\< -1.2 = moderate response, DAS28-ESR ≤ 3.2 or \\> 3.2 and ≤ 5.1 at Week 48 and a change from BL to Week 48 ≥ -0.6 = no response, DAS28-ESR \\> 5.1 at Week 48 and a change from BL to Week 48 \\< -0.6 and ≥ -1.2 or ≥ -0.6 = no response.","groups":[{"description":"Participants received rituximab, 0.5 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG000","title":"Rituximab Low Dose + Methotrexate"},{"description":"Participants received rituximab, 0.5 g, IV, on Days 1 and 15 and 1.0 g, IV, on Days 168 and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG001","title":"Rituximab Escalated Dose + Methotrexate"},{"description":"Participants received rituximab, 1.0 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG002","title":"Rituximab High Dose + Methotrexate"}],"paramType":"NUMBER","populationDescription":"ITT-M2 population","reportingStatus":"POSTED","timeFrame":"Week 48","title":"Percentage of Participants With a Response at Week 48 by European League Against Rheumatism (EULAR) Category","type":"SECONDARY","unitOfMeasure":"percentage of participants"}